ReviewCNS spectrums2022
Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice.
Review in CNS spectrums, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Genetic and molecular mechanisms of the FOXP2-CNTNAP2 pathway in Autism spectrum disorders and speech disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2026Pooled it
- Tardive dyskinesia in Asia- current clinical practice and the role of neurologists in the care pathway.Frontiers in neurology · 2024Pooled it
- Valbenazine Sprinkle: An Alternative Formulation of Valbenazine for Oral Administration in Patients With Dysphagia.Clinical and translational science · 2025Trial
- Feasibility, Effectiveness, and Acceptability of a Telemedicine Neurological Consultation for Drug-Induced Movement Disorders; A Randomized Pilot Study.Tremor and other hyperkinetic movements (New York, N.Y.) · 2025Trial
- Neuromodulation therapies in the management of tardive dyskinesia: A scoping review.Indian journal of psychiatry · 2026Review
- Adverse outcomes between VMAT2 and anticholinergics in tardive dyskinesia: A target trial emulation.Psychiatry and clinical neurosciences · 2026Article
- Enriching Global Perspectives Through a Regional Lens: Recognition, Assessment, and Management of Tardive Dyskinesia in Southeast Asia.Journal of movement disorders · 2026Article
- VMAT2 inhibitors for the treatment of tardive dyskinesia: a narrative review.CNS spectrums · 2025Review
- Identifying the diagnostic gap of tardive dyskinesia: an analysis of semi-structured electronic health record data.BMC psychiatry · 2025Article
- Drug-induced movement disorder: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2004 to 2024.PloS one · 2025Article
- Refractory tardive dyskinesia in the critical care setting: A case report of successful use of phenobarbital.SAGE open medical case reports · 2025Article
- Atypical Antipsychotic-Induced Tardive Dyskinesia in a Middle-Aged Schizophrenic Patient: A Case Report.Cureus · 2024Article
- Article
- An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders.CNS drugs · 2024Review
- Article
- Telehealth for Assessing and Managing Tardive Dyskinesia: Expert Insights from a Cross-Disciplinary Virtual Treatment Panel.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2023Article
- Impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world RE-KINECT study.Journal of patient-reported outcomes · 2023Article
- Cannabidiol and brain function: current knowledge and future perspectives.Frontiers in pharmacology · 2023Review
- Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents.Tremor and other hyperkinetic movements (New York, N.Y.) · 2022Review
- Case report: Pallidal deep brain stimulation for treatment of tardive dystonia/dyskinesia secondary to chronic metoclopramide medication.Frontiers in neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Accurate diagnosis and appropriate treatment of tardive dyskinesia (TD) are imperative, as its symptoms can be highly disruptive to both patients and their caregivers. Misdiagnosis can lead to incorrect interventions with suboptimal or even deleterious results. To aid in the identification and differentiation of TD in the psychiatric practice setting, we review its clinical features and movement phenomenology, as well as those of other antipsychotic-induced movement disorders, with accompanying links to illustrative videos. Exposure to dopamine receptor blocking agents (DRBAs) such as antipsychotics or antiemetics is associated with a spectrum of movement disorders including TD. The differential diagnosis of TD is based on history of DRBA exposure, recent discontinuation or dose reduction of a DRBA, and movement phenomenology. Common diagnostic challenges are the abnormal behaviors and dyskinesias associated with advanced age or chronic mental illness, and other movement disorders associated with DRBA therapy, such as akathisia, parkinsonian tremor, and tremor related to use of mood stabilizing agents (eg, lithium, divalproex). Duration of exposure may help rule out acute drug-induced syndromes such as acute dystonia or acute/subacute akathisia. Another important consideration is the potential for TD to present together with other drug-induced movement disorders (eg, parkinsonism, parkinsonian tremor, and postural tremor from mood stabilizers) in the same patient, which can complicate both diagnosis and management. After documentation of the phenomenology, severity, and distribution of TD movements, treatment options should be reviewed with the patient and caregivers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.